Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes

Li, Rui; Chowdhury, Mohammed Y.E.; Kim, Jae-Hoon; Kim, Tae‐Hwan; Pathinayake, Prabuddha S; Koo, Wan-Seo; Park, Min-Eun; Yoon, Jiwon; Roh, Jong-Bok; Hong, Sung-Ho; Sung, Moon-Hee; Lee, Jong-Soo; Kim, Chul-Joong

doi:10.1016/j.vetmic.2015.07.020

Cited by 31 publications

(26 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Outcomes included an increase in IgG and mucosal sIgA, increased protection against pathogen challenge, increased T cell responses (CD4 + and CD8 + ), and an increase in IFN-γ, IL-4, and IL-17. Of interest, studies utilizing CT subunits showed an immune response that was more Th1 polarized (increased IFN-γ) while studies using LT as an adjuvant resulted in both Th1 and Th2 responses (increased IFN-γ and IL-4) [84][85][86][87][88].…”

Section: Secretion Of Bacterial Toxinsmentioning

confidence: 99%

Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines

Vilander

Dean

2019

Vaccines

View full text Add to dashboard Cite

Lactic acid bacteria (LAB) are Gram-positive, acid-tolerant bacteria that have long been used in food fermentation and are generally recognized as safe (GRAS). LAB are a part of a normal microbiome and act as probiotics, improving the gastrointestinal microbiome and health when consumed. An increasing body of research has shown the importance of the microbiome on both mucosal immune heath and immune response to pathogens and oral vaccines. Currently, there are few approved mucosal vaccines, and most are attenuated viruses or bacteria, which necessitates cold chain, carries the risk of reversion to virulence, and can have limited efficacy in individuals with poor mucosal health. On account of these limitations, new types of mucosal vaccine vectors are necessary. There has been increasing interest and success in developing recombinant LAB as next generation mucosal vaccine vectors due to their natural acid and bile resistance, stability at room temperature, endogenous activation of innate and adaptive immune responses, and the development of molecular techniques that allow for manipulation of their genomes. To enhance the immunogenicity of these LAB vaccines, numerous adjuvant strategies have been successfully employed. Here, we review these adjuvant strategies and their mechanisms of action which include: Toll-like receptor ligands, secretion of bacterial toxins, secretion of cytokines, direct delivery to antigen presenting cells, and enterocyte targeting. The ability to increase the immune response to LAB vaccines gives them the potential to be powerful mucosal vaccine vectors against mucosal pathogens.

show abstract

Section: Secretion Of Bacterial Toxinsmentioning

confidence: 99%

Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines

Vilander

Dean

2019

Vaccines

View full text Add to dashboard Cite

show abstract

“…получил кан-дидатную рекомбинантную вакцину pgsACTA1sM2HA2/L.casei на основе бактерии Lactobacillus casei, экспрессирующей гены бел-ков sM2 (консенсусный между вируса грип-па А подтипов H1N1, H5N1 и H9N2 белок М2, лишенный трансмембранного домена), фраг-мента стволовой части НА (15-137 а.к.) от ви-руса гриппа A/EM/Korea/W149/06 (H5N1) и субъединицы холерного токсина А1 [56]. Препарат продемонстрировал способность индуцировать гуморальный (в том числе му-козальный) и клеточный иммунный ответ у мышей при пероральном и интраназальном введении и, кроме того, индуцировать за-щиту против 10ЛД 50 [56].…”

Section: кандидатные вакцины на основе стволовой части гемагглютининаunclassified

“…от ви-руса гриппа A/EM/Korea/W149/06 (H5N1) и субъединицы холерного токсина А1 [56]. Препарат продемонстрировал способность индуцировать гуморальный (в том числе му-козальный) и клеточный иммунный ответ у мышей при пероральном и интраназальном введении и, кроме того, индуцировать за-щиту против 10ЛД 50 [56].…”

Section: кандидатные вакцины на основе стволовой части гемагглютининаunclassified

Current Approaches to Universal Vaccine Against Influenza Virus

Булатович

Alekseeva

Саядян

et al. 2016

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Influenza is a seasonal infectious disease widespread across the globe. In Russia the share of influenza and other acute respiratory viral infections account for up to 90% of all infectious diseases. Scientific and reasonable method of influenza prevention is vaccination. However, traditional current influenza vaccines can’t induce protection against various virus strains that differ substantially in terms of their antigenic structure, and thus require periodic updates to its immunogenic components. In addition, there is the risk of a pandemic caused by an entirely new antigen in relation to variants of influenza virus A. Attempts to improve on traditional approaches to vaccination have focused primarily on improving production technologies and to increase immunogenicity of vaccines. Therefore, the urgent task is the creation of vaccines able to induce immune response a broad spectrum against different influenza virus strains and human strains of avian influenza, also can cause disease in humans. Protective effect of universal vaccine should be the induction of integrated immune response, based on the formulation of cross-reactive antibodies and T cells. The development of such universal vaccine could remove the need for periodical strain composition update of existing vaccines and, accor dingly, will be able to give the vaccine manufacturer itself, production planning regardless of epidemic seasons. Currently, the most widely studied antigens as key components of flu vaccines are proteins M2 and NP as well as the hemagglutinin of influenza virus. This review summarizes and lists some data of domestic and foreign research on a universal influenza virus vaccine.

show abstract

“…Proof-of-principle studies have demonstrated that lactobacilli-based vaccine platforms are promising candidates for mucosal vaccination against a variety of pathogens including influenza, anthrax, severe acute respiratory syndrome (SARS), and human immunodeficiency virus (HIV) [3][4][5][6]. Lactobacilli are an attractive vaccine vehicle because they persist in the gastrointestinal tract, adhere to epithelial cells, and modulate the immune response through pattern recognition receptors (PRR) (reviewed in [7][8][9][10]).…”

mentioning

confidence: 99%

“…All animals were age matched (8-12 weeks), maintained in specific pathogen free conditions, individually tracked and monitored daily for clinical signs of stress or illness, including but not limited to changes in skin and hair, eyes and mucous membranes, respiratory system, circulatory system, central nervous system, salivation, diarrhea, or lethargy. Upon arrival, animals were housed socially (2)(3)(4)(5) in commercially available, individually ventilated caging systems with a 12 h light/12 h dark cycle. Animals were provided ad libitum commercial irradiated rodent chow (Teklad Global) and tap water filtered via reverse osmosis in autoclaved water bottles; all bedding and enrichment materials was autoclaved prior to use and changed regularly.…”

mentioning

confidence: 99%

Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform

et al. 2018

View full text Add to dashboard Cite

Safe and efficacious orally-delivered mucosal vaccine platforms are desperately needed to combat the plethora of mucosally transmitted pathogens. Lactobacillus spp. have emerged as attractive candidates to meet this need and are known to activate the host innate immune response in a species- and strain-specific manner. For selected bacterial isolates and mutants, we investigated the role of key innate immune pathways required for induction of innate and subsequent adaptive immune responses. Co-culture of murine macrophages with L. gasseri (strain NCK1785), L. acidophilus (strain NCFM), or NCFM-derived mutants—NCK2025 and NCK2031—elicited an M2b-like phenotype associated with TH2 skewing and immune regulatory function. For NCFM, this M2b phenotype was dependent on expression of lipoteichoic acid and S layer proteins. Through the use of macrophage genetic knockouts, we identified Toll-like receptor 2 (TLR2), the cytosolic nucleotide-binding oligomerization domain containing 2 (NOD2) receptor, and the inflammasome-associated caspase-1 as contributors to macrophage activation, with NOD2 cooperating with caspase-1 to induce inflammasome derived interleukin (IL)-1β in a pyroptosis-independent fashion. Finally, utilizing an NCFM-based mucosal vaccine platform with surface expression of human immunodeficiency virus type 1 (HIV-1) Gag or membrane proximal external region (MPER), we demonstrated that NOD2 signaling is required for antigen-specific mucosal and systemic humoral responses. We show that lactobacilli differentially utilize innate immune pathways and highlight NOD2 as a key mediator of macrophage function and antigen-specific humoral responses to a Lactobacillus acidophilus mucosal vaccine platform.

show abstract

Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes

Cited by 31 publications

References 73 publications

Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines

Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines

Current Approaches to Universal Vaccine Against Influenza Virus

Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform

Contact Info

Product

Resources

About